Mycoplasma pneumoniae e sindrome di Stevens-Johnson / necrolisi epidermica tossica: descrizione di un caso clinico

1.Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: A Pooled Analysis. Pediatrics 2009;123;e297-e304. 2.Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens Johnson syndrome and erythema multiforme. Arch Dermatol 1993;129:92-6. 3.Roujeau JC. Stevens Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997;24:726-9. 4.French LE. Toxic Epidermal Necrolysis and Stevens Johnson Syndrome: Our Current Understanding. Allergol Int 2006;55:9-16. 5.Wolkenstein P, Chosidow O, Flechet ML, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996;35:234-6. 6.Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics 2007;120:e1082-96. 7.Ravin KA, Rappaport LD, Zuckerbraun NS, et al. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics 2007;119:e1002-5. 8.Hammerschlag MR. Mycoplasma pneumoniae infections. Curr Opin Infect Dis 2001;14:181-6. 9.Linz DH, Tolle SW, Elliot DL. Mycoplasma pneumoniae pneumonia: experience at a referral center. West J Med 1984;140:895-900. 10.Salierno P, Lazzerini M, Marchetti F. La sindrome di Stevens-Johnson: antibiotico o infezione? Medico e Bambino pagine elettroniche 2006;9(1) http://www.medicoebambino.com/_sindrome_stevens_johnson_lesioni_cutanee_edema_orale_labbra. 11.Léauté-Labrèze C, Lamireau T, Chawki D, Maleville J, Taïeb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child 2000;83:347-52. 12.Barone CM, Bianchi MA, Lee B, Mitra A. Treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome in children. J Oral Maxillofac Surg 1993;51:264-8. 13.Kakourou T, Klontza D, Soteropoulou F, Kattamis C. Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. Eur J Pediatr 1997;156:90-3. 14.Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermalol 2000;1:349-60. 15.Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-93. 16.Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol 2005;71:398-400. 17.Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002;47:548-52. 18.Zipitis CS, Thalange N. Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations. Eur J Pediatr 2007;166:585-8. 19.Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Chinese patients: a retrospective study of 82 cases. Eur J Dermatol 2010;20:743-7.